Colistimethate
Articles · Lactation Safety Information · New Medicines · Published , updated
422267005
Articles
27th February 2020
Which commonly used nebuliser solutions are compatible?
Mixing of nebuliser solutions should only be undertaken in the best interests of the patient and only by a person competent and willing to do… Budesonide Colistimethate Fluticasone Ipratropium Pharmaceutical Stability Q&A Respiratory disorders Salbutamol Salbutamol + Ipratropium Terbutaline Tobramycin
20th February 2018
How should antibiotics be dosed in obesity?
The Q&A produced in 2013 has been updated and published on the Scottish Antimicrobial Prescribing Group (SAPG) website. A review of the evidence was carried… Amikacin Ciprofloxacin Clindamycin Colistimethate Daptomycin Gentamicin Infection and infectious diseases Levofloxacin Linezolid Medicine Moxifloxacin Q&A Teicoplanin Tobramycin Vancomycin
20th May 2012
Safety in Lactation: Some other antibacterials
Monitor infant for gastro-intestinal disturbances and oral candida infection, especially if used for prolonged periods or in high doses, although these effects are unlikely to… Chloramphenicol Colistimethate Daptomycin Linezolid Rifaximin Sodium fusidate Teicoplanin VancomycinLactation Safety Information
Minimal absorption from the infant's GI tract
No published evidence of safety
Small amounts in breast milk
24th September 2020
New Medicines
Promixin · Non-cystic fibrosis (CF)-related bronchiectasis - first-line in patients colonised with Pseudomonas aeruginosa
Information
Promixin
Licence extension / variation
Zambon
Zambon
Development and Regulatory status
Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Category
The pentasodium salt derivative of colistin, a polypeptide antibiotic produced by Bacillus polymyxa var. colistinus
A large study across 640 general practices in the UK found that prevalence in 2011 in men was 227 per 100,000, and 309 per 100,000 in women. It is estimated that around 1,000 people die each year from bronchiectasis in England and Wales. Chronic colonisation by P. aeruginosa, severe exacerbations, and systemic inflammation (raised C-reactive protein) are associated with disease progression in non-cystic fibrosis bronchiectasis. 10% of adults die within 5-8 years of diagnosis [1].
Non-cystic fibrosis (CF)-related bronchiectasis - first-line in patients colonised with Pseudomonas aeruginosa
Inhalation